切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2025, Vol. 14 ›› Issue (02) : 274 -280. doi: 10.3877/cma.j.issn.2095-3232.2025035

临床研究

新辅助治疗后“二步法”改良Appleby 术治疗局部进展期胰体癌
颜军1, 郭诗翔1, 吴堃1,()   
  1. 1. 401147 重庆市人民医院肝胆胰腺外科
  • 收稿日期:2024-11-22 出版日期:2025-04-10
  • 通信作者: 吴堃
  • 基金资助:
    重庆市科卫联合医学科研项目(2024MSXM174)重庆市卫生健康委医学科研项目(2024WSJK052)

Modified “two-step” Appleby operation after neoadjuvant therapy for locally advanced pancreatic body cancer

Jun Yan1, Shixiang Guo1, Kun Wu1,()   

  1. 1. Department of Hepatobiliary and Pancreatic Surgery, Chongqing People’s Hospital, Chongqing 401147, China
  • Received:2024-11-22 Published:2025-04-10
  • Corresponding author: Kun Wu
引用本文:

颜军, 郭诗翔, 吴堃. 新辅助治疗后“二步法”改良Appleby 术治疗局部进展期胰体癌[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 274-280.

Jun Yan, Shixiang Guo, Kun Wu. Modified “two-step” Appleby operation after neoadjuvant therapy for locally advanced pancreatic body cancer[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 274-280.

目的

探讨新辅助治疗后“二步法”改良Appleby 术治疗局部进展期胰体癌的应用价值。

方法

回顾总结2021 年6 月至2022 年6 月重庆市人民医院收治的2 例局部进展期胰体癌患者临床资料。患者均签署知情同意书,符合医学伦理学规定。患者均为男性,年龄分别为56、64 岁。CA19-9 分别为901、613 kU/L,肿瘤直径分别为8.9、3.6 cm。2 例患者经超声内镜引导下胰腺穿刺活检确诊为胰腺导管腺癌,MDT 讨论后行3 个周期的新辅助化疗,方案为吉西他滨联合白蛋白结合型紫杉醇,未联用靶免治疗。新辅助治疗后1~3 周内行“二步法”改良Appleby 手术。分析2 例患者新辅助治疗后肿瘤变化情况、手术完成情况、术后并发症以及生存情况等。

结果

新辅助治疗后2 例患者CA19-9 明显下降,下降幅度超过50%,肿瘤明显缩小伴血管侵犯减小,手术指征明确。手术方案:第一步肝总动脉预处理,腹腔镜下肝总动脉结扎术,术后肝功能轻度异常,2 周内恢复正常,影像学提示肝脏、胃肠道血供良好;第二步充分术前准备后行改良Appleby 手术。术后出现转氨酶一过性升高,予以保肝治疗后好转;CA19-9 水平进一步下降,影像学提示肝脏、胃肠道血供良好,未出现缺血性病变,顺利康复出院。2 例患者术后均继续行辅助化疗,方案为吉西他滨联合白蛋白结合型紫杉醇。例1 术后13 个月出现全身多处转移,例2 术后15 个月出现肝转移,截止投稿日期仍存活。

结论

局部进展期胰体癌新辅助治疗后行改良Appleby 术可提高手术R0 切除率,“二步法”的手术设计可减少术后相关缺血性病变发生,降低围手术期并发症发生率,临床应用安全、可行。

Objective

To evaluate the application value of modified “two-step” Appleby operation after neoadjuvant therapy in the treatment of locally advanced pancreatic body cancer.

Methods

Clinical data of two patients with locally advanced pancreatic body cancer admitted to Chongqing People’s Hospital from June 2021 to June 2022 were retrospectively analyzed.The informed consents of all patients were obtained and the local ethical committee approval was received.Both two patients were male, aged 56 and 64 years, respectively.CA19-9 level was 901 and 613 kU/L, and tumor diameter was 8.9 and 3.6 cm,respectively.Two patients were diagnosed with pancreatic ductal adenocarcinoma by endoscopic ultrasoundguided pancreatic biopsy.After MDT consultation, three cycles of neoadjuvant chemotherapy were performed.The regimen consisted of gemcitabine combined with albumin-bound paclitaxel, without targeted immunotherapy.Modified “two-step” Appleby operation was performed within 1-3 weeks after neoadjuvant therapy.The tumor changes, surgical completion, postoperative complications and survival of two patients after neoadjuvant therapy were analyzed.

Results

After neoadjuvant therapy, CA19-9 level was decreased significantly by over 50% in two patients.The tumor size was evidently reduced accompanied with decrease of vascular invasion, and surgical indications were evident.Surgical regimen: at the first step, common hepatic artery pretreatment, laparoscopic ligation of common hepatic artery were performed.Postoperatively,liver function was slightly abnormal and restored to normal within 2 weeks.Imaging examination indicated that the blood supply of liver and gastrointestinal tract was normal.At the second step, modified Appleby operation was performed after comprehensive preoperative preparation.Transient elevation of transaminase level occurred after operation, which was improved after liver-protection treatment.CA19-9 level was further decreased.Imaging examination showed that the blood supply of liver and gastrointestinal tract was normal,and no ischemic lesion was found.Two patients were discharged after recovery.Postoperatively, two patients continued to receive adjuvant chemotherapy of gemcitabine combined with albumin-bound paclitaxel.One patient developed multiple systemic metastases at 13 months after operation, and the other patient had liver metastases at postoperative 15 months.Both two patients survived as of the paper submission date.

Conclusions

Modified Appleby operation after neoadjuvant therapy can improve the R0 resection rate for locally advanced pancreatic body cancer.“Two-step” surgical design can reduce the incidence of postoperative ischemic lesions and perioperative complications, which is safe and feasible in clinical application.

表1 两例局部进展期胰体癌患者新辅助化疗前后临床指标
图1 例2 局部进展期胰体癌患者改良Appleby 术中情况 注:GDA 为胃十二指肠动脉,HA Stump 为肝总动脉断端,CA Stump 为腹腔干断端,SMA 为肠系膜上动脉,LRV 为左肾静脉,LRA 为左肾动脉
图2 例1 局部进展期胰体癌患者腹部CT 动脉期图像 注: a、b 分别为肝总动脉预处理前后,示肝脏内动脉血供良好,肝脏无坏死、无脓肿,肠系膜上动脉、胃十二指肠动脉、肝固有动脉通畅;c 为改良Appleby 术后示十二指肠动脉、肝固有动脉及肝内动脉供血良好
[1]
Siegel R, Miller KD, Fuchs HE, et al.Cancer statistics, 2021[J].CA A Cancer J Clin, 2021, 71: 33-37.DOI: 10.3322/caac.21654.
[2]
Chen X, Yi B, Liu Z, et al.Global, regional and national burden of pancreatic cancer, 1990 to 2017: results from the Global Burden of Disease Study 2017[J].Pancreatology, 2020, 20(3): 462-469.DOI:10.1016/j.pan.2020.02.011.
[3]
Yamamoto T, Satoi S, Kawai M, et al.Is distal pancreatectomy with enbloc celiac axis resection effective for patients with locally advanced pancreatic ductal adenocarcinoma?: multicenter surgical group study[J].Pancreatology, 2018, 18(1): 106-113.DOI: 10.1016/j.pan.2017.11.005.
[4]
Appleby LH.The coeliac axis in the expansion of the operation for gastric carcinoma[J].Cancer, 1953, 6(4): 704-707.DOI: 10.1002/1097-0142(195307)6: 4<704: aid-cncr2820060410>3.0.co;2-p.
[5]
Morris M, Price T, Callahan Z, et al.Celiac axis resection with distal pancreatectomy (modified appleby procedure) allows for R0 resection of pancreatic body and tail mass following neoadjuvant therapy: case report and literature review[J].Case Rep Pancreat Cancer, 2016, 2(1):53-57.DOI: 10.1089/crpc.2016.0011.
[6]
Mayumi T, Nimura Y, Kamiya J, et al.Distal pancreatectomy with en bloc resection of the celiac artery for carcinoma of the body and tail of the pancreas[J].Int J Pancreatol, 1997, 22(1): 15-21.DOI: 10.1007/BF02803900.
[7]
Tempero MA, Malafa MP, Gabriela Chiorean E, et al.Pancreatic adenocarcinoma, version 1.2019[J].J Natl Compr Canc Netw, 2019,17(3): 202-210.DOI: 10.6004/jnccn.2019.0014.
[8]
Yamamoto Y, Sakamoto Y, Ban D, et al.Is celiac axis resection justified for T4 pancreatic body cancer?[J].Surgery, 2012, 151(1): 61-69.DOI: 10.1016/j.surg.2011.06.030.
[9]
Takahashi Y, Kaneoka Y, Maeda A, et al.Distal pancreatectomy with celiac axis resection for carcinoma of the body and tail of the pancreas[J].World J Surg, 2011, 35(11): 2535-2542.DOI: 10.1007/s00268-011-1245-x.
[10]
Yoshiya S, Fukuzawa K, Inokuchi S, et al.Efficacy of neoadjuvant chemotherapy in distal pancreatectomy with en bloc celiac axis resection (DP-CAR) for locally advanced pancreatic cancer[J].J Gastrointest Surg, 2020, 24(7): 1605-1611.DOI: 10.1007/s11605-019-04324-8.
[11]
Murakami Y, Nakagawa N, Kondo N, et al.Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma[J].Pancreatology, 2021, 21(3):564-572.DOI: 10.1016/j.pan.2021.01.008.
[12]
Gong H, Ma R, Gong J, et al.Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer: a systematic review and meta-analysis[J].Medicine, 2016, 95(10):e3061.DOI: 10.1097/MD.0000000000003061.
[13]
Eisenhauer EA, Therasse P, Bogaerts J, et al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J].Eur J Cancer, 2009, 45(2): 228-247.DOI: 10.1016/j.ejca.2008.10.026.
[14]
Tol JAMG, Gouma DJ, Bassi C, et al.Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS)[J].Surgery, 2014, 156(3): 591-600.DOI: 10.1016/j.surg.2014.06.016.
[15]
Dindo D, Demartines N, Clavien PA.Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey[J].Ann Surg, 2004, 240(2): 205-213.DOI: 10.1097/01.sla.0000133083.54934.ae.
[16]
Wente MN, Bassi C, Dervenis C, et al.Delayed gastric emptying(DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS)[J].Surgery,2007, 142(5): 761-768.DOI: 10.1016/j.surg.2007.05.005.
[17]
Wente MN, Veit JA, Bassi C, et al.Postpancreatectomy hemorrhage(PPH): an international study group of pancreatic surgery (ISGPS)definition [J].Surgery, 2007, 142(1): 20-25.DOI: 10.1016/j.surg.2007.02.001.
[18]
Bassi C, Marchegiani G, Dervenis C, et al.The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after[J].Surgery, 2017,161(3): 584-591.DOI: 10.1016/j.surg.2016.11.014.
[19]
Nakamura T, Hirano S, Noji T, et al.Distal pancreatectomy with en bloc celiac axis resection (modified appleby procedure) for locally advanced pancreatic body cancer: a single-center review of 80 consecutive patients[J].Ann Surg Oncol, 2016, 23(Suppl 5): 969-975.DOI: 10.1245/s10434-016-5493-8.
[20]
Yamaguchi K, Nakano K, Kobayashi K, et al.Appleby operation for pancreatic body-tail carcinoma: report of three cases[J].Surg Today,2003, 33(11): 873-878.DOI: 10.1007/s00595-003-2602-7.
[21]
Mitchem JB, Hamilton N, Gao F, et al.Long-term results of resection of adenocarcinoma of the body and tail of the pancreas using radical antegrade modular pancreatosplenectomy procedure[J].J Am Coll Surg, 2012, 214(1): 46-52.DOI: 10.1016/j.jamcollsurg.2011.10.008.
[22]
Abe T, Ohuchida K, Miyasaka Y, et al.Comparison of surgical outcomes between radical antegrade modular pancreatosplenectomy(RAMPS) and standard retrograde pancreatosplenectomy (SPRS) for left-sided pancreatic cancer[J].World J Surg, 2016, 40(9): 2267-2275.DOI: 10.1007/s00268-016-3526-x.
[23]
Peters NA, Javed AA, Cameron JL, et al.Modified appleby procedure for pancreatic adenocarcinoma: does improved neoadjuvant therapy warrant such an aggressive approach?[J].Ann Surg Oncol, 2016,23(11): 3757-3764.DOI: 10.1245/s10434-016-5303-3.
[24]
Kluger MD, Farzan Rashid M, Rosario VL, et al.Resection of locally advanced pancreatic cancer without regression of arterial encasement after modern-era neoadjuvant therapy[J].J Gastrointest Surg, 2018,22(2): 235-241.DOI: 10.1007/s11605-017-3556-1.
[25]
中华人民共和国国家卫生健康委员会医政医管局.胰腺癌诊疗指南(2022年版)[J].中华消化外科杂志, 2022, 21(9): 1117-1136.DOI:10.3760/cma.j.cn115610-20220726-00431.Bureau of Medical Administration of National Health Commission of the People’s Republic of China.Standardization for diagnosis and treatment of pancreatic cancer(2022 edition)[J].Chin J Dig Surg,2022, 21(9): 1117-1136.DOI: 10.3760/cma.j.cn115610-20220726-00431.
[26]
杨尹默, 李宝毅, 马永蔌.胰腺癌免疫治疗现状与进展[J].中华普通外科杂志, 2023, 38(5): 321-325.DOI: 10.3760/cma.j.cn113855-20230322-00141.Yang YM, Li BY, Ma YS.Current Status and progress of immunotherapy in pancreatic cancer[J].Chin J Gen Surg, 2023, 38(5): 321-325.DOI:10.3760/cma.j.cn113855-20230322-00141.
[27]
Dhir M, Zenati MS, Hamad A, et al.FOLFIRINOX versus gemcitabine/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic head adenocarcinoma[J].Ann Surg Oncol, 2018, 25(7): 1896-1903.DOI: 10.1245/s10434-018-6512-8.
[28]
Klompmaker S, van Hilst J, Gerritsen SL, et al.Outcomes after distal pancreatectomy with celiac axis resection for pancreatic cancer: a pan-European retrospective cohort study[J].Ann Surg Oncol, 2018, 25(5):1440-1447.DOI: 10.1245/s10434-018-6391-z.
[29]
Kondo S, Katoh H, Shimizu T, et al.Preoperative embolization of the common hepatic artery in preparation for radical pancreatectomy for pancreas body cancer[J].Hepatogastroenterology, 2000, 47(35): 1447-1449.
[30]
Abo D, Hasegawa Y, Sakuhara Y, et al.Feasibility of a dual microcatheter-dual interlocking detachable coil technique in preoperative embolization in preparation for distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer[J].J Hepatobiliary Pancreat Sci, 2012, 19(4): 431-437.DOI:10.1007/s00534-011-0455-9.
[31]
Ueda A, Sakai N, Yoshitomi H, et al.Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer?[J].World J Surg Oncol, 2019, 17(1): 124.DOI: 10.1186/s12957-019-1667-8.
[1] 张群, 李俊杰. 乳腺癌外科十大热点[J/OL]. 中华乳腺病杂志(电子版), 2025, 19(01): 6-11.
[2] 杨颖, 辛岗, 王丽君, 胡崇珠. 吡咯替尼新辅助治疗HER-2 阳性乳腺癌的研究现状[J/OL]. 中华乳腺病杂志(电子版), 2025, 19(01): 58-60.
[3] 虞先濬. 胰腺肿瘤外科:外科学遇见肿瘤学——拥抱精准、走向卓越[J/OL]. 中华普通外科学文献(电子版), 2025, 19(01): 27-27.
[4] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[5] 姚宏伟, 孙丽婷, 吴偲, 舒文龙, 高加勒, 杨正阳, 吴国聪, 张忠涛. 新辅助放化疗联合免疫治疗局部进展期直肠癌的探索与实践[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 123-127.
[6] 王乾宇, 杜峻峰, 李世拥. 新辅助放化疗联合免疫治疗局部进展期直肠癌的突破与挑战[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 128-131.
[7] 邓崇文, 廖喜望, 施幼雄, 龚俊, 钟洪. 腹腔镜下胃癌D2根治+腹主动脉旁淋巴结清扫术治疗局部进展期胃癌的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 180-183.
[8] 丁志文, 赵一鸣, 王鲁. 肝内胆管癌手术与综合治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 187-196.
[9] 杨陈凤麟, 张潇, 丁洁茹, 胡文, 李尧, 陈品初, 王泽桐, 张起帆. 转化治疗后肝癌肝切除患者术后自发性胆漏发生原因初步探讨[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 256-261.
[10] 孙志鹏, 束斌, 王良, 黄鑫, 王鹏飞, 李广欣, 王小娟, 黎功, 杨世忠. 放疗联合靶向免疫新辅助治疗肝内胆管细胞癌的安全性与疗效[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 92-96.
[11] 李伟男, 杨刚, 熊永福, 李强, 李敬东. 中晚期肝癌TACE 联合靶向免疫转化治疗后成功实施ALPPS 的初步经验[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 97-101.
[12] 黄忠晶, 张丽东, 伍子奕, 艾军华. 不可切除肝细胞癌的转化治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 41-45.
[13] 王闪闪, 赵海涛. 胆道癌转化手术策略[J/OL]. 中华消化病与影像杂志(电子版), 2025, 15(01): 1-5.
[14] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[15] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
阅读次数
全文


摘要